A Bioequivalence Study of Sacubitril/Valsartan Film-coated Tablets Under Fasting Conditions

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

May 31, 2024

Study Completion Date

September 30, 2024

Conditions

Bioequivalence Study

Interventions

DRUG

Sacubitril and Valsartan Tablets 49mg/51mg

Each tablet contains Sacubitril 49 mg and Valsartan 51 mg

DRUG

Entresto® (Sacubitril and Valsartan Tablets 49mg/51mg)

Each tablet contains 48.6 mg sacubitril and 51.4 mg valsartan as sodium salt complex

Trial Locations (1)

Medica Innova Co Ltd, Bangkok

All Listed Sponsors

lead

Viatris Inc.

INDUSTRY